The global Blood Screening Market is experiencing robust growth due to an alarming prevalence of infectious diseases and an expanding geriatric population. Age-related health conditions and a growing susceptibility to chronic illnesses among the elderly have significantly increased the demand for blood screening. Additionally, a consistent rise in blood donation programs and the frequency of blood transfusions in hospitals and other healthcare settings further necessitate blood screening, driving market growth. However, the lack of standardization regarding blood transfusion procedures, a complex regulatory approval framework, and a severe dearth of skilled manpower continue to impede rapid market expansion, especially in developing economies. Emerging alternative testing techniques like digital immunoassay are also expected to pose a challenge to market growth in the near future.
Visit our Research Report: https://www.fairfieldmarketresearch.com/report/blood-screening-market Key Drivers of Market Growth Mandatory blood screening for the presence of red cell antibodies and infectious disease agents such as HIV-1 and -2, hepatitis virus, T. pallidum (syphilis), human Tlymphotropic virus (HTLV), T. Cruzi, and West Nile virus (WNV) are significant factors contributing to the growth of the global blood screening market. Opportunities are emerging with the introduction of microbiology screening, multiplexing for HIV, HBV, and HCV, and pathogen reduction technology. Blood screenings during pregnancy phases to detect possible prenatal abnormalities also strongly encourage the demand for blood screening. Tests like western blot assay, next-generation sequencing (NGS), and enzyme-linked immunosorbent assay (ELISA) continue to uphold the market's growth prospects.